Overexpression of CD59 inhibits apoptosis of T-acute lymphoblastic leukemia via AKT/Notch1 signaling pathway

Yanfei Jia, Yan Qi, Yunshan Wang, Xiaoli Ma, Yihui Xu, Jun Wang, Xiaoqian Zhang, Meihua Gao, Beibei Cong, Shuyi HanCancer 2019 · DOI

Abstract

CD59 inhibited apoptosis of T-ALL by regulating AKT/Notch1 signaling pathway, providing a new perspective for the treatment of T-ALL.

Introduction

T-acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy characterized by the uncontrolled proliferation of immature T-cell precursors. Despite advances in treatment, approximately 15% of pediatric and 40% of adult patients experience relapse, often due to treatment resistance.

CD59 is a glycosylphosphatidylinositol (GPI)-anchored membrane protein traditionally known for its role in protecting cells from complement-mediated lysis by inhibiting the formation of the membrane attack complex (MAC). While its role in immune evasion is well-documented in various solid tumors, its potential function as an active driver of oncogenic signaling in T-ALL has remained largely unexplored. This study investigates whether CD59 contributes to T-ALL progression by directly modulating cell survival and apoptosis pathways.

Methods

The study utilized a multi-tiered experimental approach combining clinical data, genetic engineering, and animal models:

  • Clinical Profiling: Bone marrow samples from 17 T-ALL patients and 38 healthy participants were analyzed using flow cytometry to establish baseline CD59 expression levels.
  • Genetic Manipulation: Using the Jurkat cell line, the researchers created variants overexpressing wild-type CD59, knockdown (KD) variants, and specific point mutations (W40A and K41A) to identify functional domains.
  • In Vitro and In Vivo Assays: Cell viability and apoptosis were tracked via CCK8 and Western blotting (targeting AKT, STAT5, and Notch1). Engineered cells were also transplanted into nude mice to observe tumor progression and cytokine (IL-2) secretion in a living system.

Results

Clinical Evidence of CD59 Overexpression

Clinical data revealed that T-ALL patients have significantly higher proportions of CD59+ T cells in their bone marrow (~16.4%) compared to healthy individuals (~6.2%). This suggests that CD59 expression is upregulated during the progression of the disease.

Figure 6: Comparison of CD59 expression between healthy participants and T-ALL patients, showing significantly higher CD59+ cell percentages in the patient group.

CD59 as a Survival Signal

Beyond its role as an "immune shield," CD59 acts as a signaling hub. Its overexpression significantly up-regulated anti-apoptotic proteins (Bcl-2) and down-regulated pro-apoptotic ones (Bax, Caspase 3). By mutating specific amino acids, the researchers found that Trp40 (W40) is the critical functional site; when W40 was mutated, CD59 lost its ability to protect the cells and activate survival pathways.

The study demonstrated that CD59 expression correlates with the activation of Notch1 and AKT, both notorious drivers of T-ALL. Western blots confirmed that high CD59 levels increased the phosphorylation of AKT and STAT5, and increased the expression of Notch1 and its target gene, HEY1. When an AKT inhibitor (LY294002) was used, the protective effects of CD59 vanished, proving that CD59 relies on this specific signaling circuit to prevent cancer cell death.

Discussion and Conclusion

This research identifies CD59 as a functional signaling molecule that actively promotes T-ALL cell survival. While the clinical sample size was relatively small, the consistent results across cell lines and animal models provide strong evidence for CD59's role in leukemia progression.

In conclusion, CD59 inhibits apoptosis of T-ALL by regulating the AKT/Notch1 signaling pathway. These findings identify CD59 as a promising new target for therapeutic intervention, potentially offering a way to overcome treatment resistance in T-ALL patients.

Summary updated

Abstract

In conclusion, CD59 inhibited apoptosis of T-ALL by regulating AKT/Notch1 signaling pathway, providing a new perspective for the treatment of T-ALL.
BibTeX
@inproceedings{jia2019overexpression,
  author = {Yanfei Jia and Yan Qi and Yunshan Wang and Xiaoli Ma and Yihui Xu and Jun Wang and Xiaoqian Zhang and Meihua Gao and Beibei Cong and Shuyi Han},
  title = {{Overexpression of CD59 inhibits apoptosis of T-acute lymphoblastic leukemia via AKT/Notch1 signaling pathway}},
  booktitle = {Cancer},
  year = {2019},
  doi = {10.1186/s12935-018-0714-9},
}
Figure